US · NVO
Novo Nordisk A/S
- Sector
- Healthcare · Drug Manufacturers - General
- Headquarters
- Bagsvaerd 2880
- Website
- novonordisk.com
Price · as of 2025-12-31
$43.88
Market cap 166.46B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $9.40 | -78.58% |
| Intrinsic Value(DCF) | $40.17 | -8.45% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $36.20 | -17.5% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $10.66 | $11.14 | $9.48 | $1.00 | $8.00 |
| 2012 | $13.40 | $13.24 | $20.55 | $0.90 | $15.30 |
| 2013 | $18.53 | $15.98 | $15.36 | $0.70 | $11.00 |
| 2014 | $18.96 | $17.03 | $13.21 | $0.00 | $11.10 |
| 2015 | $23.07 | $22.18 | $23.26 | $0.80 | $30.50 |
| 2016 | $14.09 | $16.88 | $18.70 | $0.00 | $13.60 |
| 2017 | $21.79 | $20.10 | $13.52 | $0.00 | $9.80 |
| 2018 | $21.78 | $20.95 | $8.68 | $0.00 | $10.40 |
| 2019 | $28.10 | $24.00 | $10.40 | $0.00 | $21.80 |
| 2020 | $32.60 | $28.97 | $12.06 | $0.00 | $16.90 |
| 2021 | $47.40 | $31.51 | $20.09 | $0.00 | $30.40 |
| 2022 | $67.14 | $47.74 | $49.66 | $0.00 | $62.70 |
| 2023 | $128.09 | $84.61 | $161.94 | $1.50 | $111.10 |
| 2024 | $84.83 | $76.33 | $266.17 | $0.00 | $113.90 |
| 2025 | $37.76 | $59.72 | $120.55 | $0.00 | $36.20 |
AI valuation
Our deep-learning model estimates Novo Nordisk A/S's (NVO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $9.40
- Current price
- $43.88
- AI upside
- -78.58%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$40.17
-8.45% upside
Graham-Dodd
—
— upside
Graham Formula
$36.20
-17.5% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NVO | Novo Nordisk A/S | $43.88 | 166.46B | +36% | -8% | — | -18% | 10.46 | 5.52 | 3.60 | 8.17 | 591.70 | 16.74 | 80.34% | 43.69% | 33.14% | 60.70% | 39.34% | 20.31% | 0.67 | 19.92 | 0.80 | 0.48 | 0.73 | 177.00% | 234.00% | -5838.00% | 2.71% | 0.55 | 11.19% | 4.65% | 48.60% | 4.77% | 9.05 | 40.54 | 3.95 | 3.59 |
| ABT | Abbott Laboratories | $116.32 | 202.45B | -26% | -58% | — | -57% | 30.56 | 3.82 | 4.50 | 17.79 | — | 8.83 | 55.51% | 18.16% | 14.72% | 13.07% | 10.95% | 7.76% | 0.29 | 23.60 | 1.58 | 1.02 | 0.57 | -5131.00% | 567.00% | 1644.00% | 3.71% | 0.58 | 13.06% | 2.06% | 63.10% | 3.07% | 25.53 | 27.79 | 4.64 | 5.28 |
| AMGN | Amgen Inc. | $387.96 | 209.14B | -9% | -34% | — | -35% | 26.91 | 23.97 | 5.65 | 15.97 | 30.50 | -6.42 | 70.80% | 29.06% | 20.99% | 106.10% | 16.96% | 8.45% | 6.31 | 3.88 | 1.14 | 0.73 | 2.87 | 8823.00% | 992.00% | -2207.00% | 3.90% | 0.39 | 14.98% | 2.47% | 66.50% | 3.75% | 23.70 | 31.23 | 6.89 | 2.36 |
| AZN | AstraZeneca PLC | $208.45 | 646.31B | -44% | -57% | -100% | -74% | 61.77 | 12.98 | 10.75 | 33.06 | 32.62 | -60.60 | 81.90% | 23.40% | 17.46% | 22.86% | 16.43% | 9.38% | 0.61 | 8.11 | 0.94 | 0.68 | 1.21 | 18938.00% | 863.00% | 6172.00% | 1.86% | 0.48 | 17.05% | 0.80% | 49.70% | 1.02% | 47.70 | 55.72 | 11.16 | 6.83 |
| GILD | Gilead Sciences, Inc. | $148.95 | 184.8B | -18% | -32% | — | -52% | 21.93 | 8.25 | 6.34 | 18.54 | 1.30 | -69.80 | 86.69% | 40.14% | 28.90% | 40.57% | 28.89% | 14.42% | 1.09 | 11.54 | 1.68 | 1.31 | 1.57 | 168421.00% | 240.00% | -824.00% | 5.07% | 0.85 | 26.61% | 2.14% | 47.00% | 3.17% | 16.98 | 21.22 | 6.81 | 4.40 |
| GSK | GSK plc | $59.13 | 119.27B | 0% | -48% | — | -38% | 15.76 | 5.39 | 2.76 | 8.81 | 13.21 | -11.95 | 72.54% | 21.95% | 17.50% | 37.25% | 20.70% | 9.28% | 1.08 | 10.23 | 0.82 | 0.52 | 1.23 | 11935.00% | 183.00% | 6306.00% | 6.61% | 0.33 | 20.23% | 2.85% | 44.90% | 2.85% | 14.61 | 17.58 | 3.21 | 2.24 |
| MRK | Merck & Co., Inc. | $123.78 | 306.03B | +5% | -27% | -61% | -44% | 16.68 | 5.79 | 4.68 | 13.42 | 208.16 | 70.05 | 81.50% | 41.19% | 28.08% | 36.91% | 29.12% | 17.40% | 0.96 | — | 1.54 | 0.96 | 1.42 | 801.00% | 131.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | 12.71 | — | 5.24 | 5.12 |
| NVS | Novartis AG | $168.62 | 325.95B | -29% | -50% | — | -40% | 23.02 | 7.01 | 5.90 | 15.18 | 102.37 | -36.57 | 75.02% | 31.15% | 25.64% | 31.17% | 21.84% | 12.91% | 0.80 | 14.38 | 1.12 | 0.83 | 1.11 | 2249.00% | 597.00% | 2811.00% | 5.47% | 0.71 | 26.49% | 2.43% | 55.90% | 5.29% | 20.44 | 19.73 | 6.37 | 4.35 |
| PFE | Pfizer Inc. | $27.65 | 157.21B | +59% | -45% | -66% | -67% | 19.93 | 1.79 | 2.48 | 13.65 | — | -4.02 | 70.33% | 24.67% | 12.42% | 8.90% | 11.33% | 3.69% | 0.75 | 5.78 | 1.16 | 0.37 | 4.22 | -355.00% | -165.00% | -773.00% | 5.86% | 0.32 | 6.66% | 0.00% | 0.00% | 1.48% | 13.35 | 22.71 | 3.29 | 2.12 |
| SNY | Sanofi | $48.66 | 117.52B | -6% | +222% | -59% | +2% | 12.72 | 1.39 | 2.13 | 8.95 | — | 26.05 | 72.34% | 13.58% | 16.72% | 10.50% | 6.06% | 6.02% | 0.31 | 11.73 | 1.09 | 0.28 | 1.11 | -731.00% | 549.00% | 5107.00% | 8.95% | 0.38 | 10.28% | 4.61% | 58.70% | 9.47% | 17.90 | 12.77 | 2.43 | 1.64 |
| TMO | Thermo Fisher Scientific … | $521.11 | 195.79B | -36% | -60% | -86% | -59% | 28.45 | 3.58 | 4.29 | 19.23 | 388.69 | -16.23 | 37.66% | 18.20% | 15.12% | 13.05% | 9.40% | 6.47% | 0.74 | 5.71 | 1.89 | 1.25 | 2.58 | 732.00% | 391.00% | -1340.00% | 3.29% | 0.51 | 7.89% | 0.33% | 9.50% | 1.90% | 27.19 | 35.04 | 4.95 | 2.81 |
About Novo Nordisk A/S
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with UNICEF to tackle childhood obesity; and with Valo Health, Inc. to discover and develop novel drug programmes for cardiometabolic space. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
- CEO
- Maziar Mike Doustdar
- Employees
- 77.41K
- Beta
- 0.40
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($40.17 ÷ $43.88) − 1 = -8.45% (DCF, example).